Published in Oncogene on September 01, 1991
p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A (1993) 1.93
Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol (1993) 1.80
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
p53 alteration in gastric precancerous lesions. Am J Pathol (1994) 1.45
Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest (1995) 1.43
Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res (2009) 1.13
p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol (1993) 1.09
Germ-line and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci U S A (1992) 1.08
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet (1993) 1.01
p53 mutations and expression in breast carcinoma in situ. Am J Pathol (2000) 0.99
Specific p53 immunostaining patterns are associated with smoking habits in patients with oral squamous cell carcinomas. J Clin Pathol (2002) 0.97
Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer (1998) 0.97
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer (1998) 0.97
Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect (1997) 0.96
p53 mutations in urinary bladder cancer. Br J Cancer (2001) 0.95
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther (2004) 0.95
p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer (1994) 0.91
p53 gene mutations in multiple myeloma. Mol Pathol (1997) 0.88
Development and progression of colorectal neoplasia. Cancer Biomark (2010) 0.85
Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction. J Cancer Res Clin Oncol (2006) 0.81
Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer (2000) 0.79
p53 gene alterations and protein accumulation in colorectal cancer. Clin Mol Pathol (1996) 0.75
Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer. Mol Pathol (2002) 0.75
p53: a frequent target for genetic abnormalities in lung cancer. Science (1989) 7.51
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res (2000) 1.64
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. Ann Thorac Surg (1989) 1.53
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst (1993) 1.50
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res (1999) 1.47
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene (1992) 1.41
Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.41
Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest (1990) 1.38
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res (1990) 1.33
Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst (1991) 1.26
Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg (2001) 1.22
Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg (1990) 1.20
Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J (2011) 1.16
Mutations in the p53 gene in primary human breast cancers. Cancer Res (1991) 1.15
Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol (2007) 1.15
Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer (2000) 1.15
A clinicopathological study of gastric cancer with special reference to age of the patients: an analysis of 1,630 cases. World J Surg (1989) 1.13
Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer (1991) 1.09
Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.07
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer (1997) 1.05
Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer (2001) 1.04
High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res (2000) 1.04
Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2. Cancer Immunol Immunother (1990) 1.04
Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br J Cancer (2001) 1.03
Multiple oral squamous epithelial lesions: are they genetically related? Oncogene (2001) 1.00
Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br J Cancer (2002) 0.98
Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest (1995) 0.98
Malignant transformation of an intrathoracic neurofibroma in von Recklinghausen's disease. Scand Cardiovasc J (1998) 0.97
Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene (1998) 0.97
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer (2007) 0.96
Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health (1995) 0.94
p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res (1998) 0.94
Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene (1992) 0.93
Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol (2001) 0.93
A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene (1993) 0.92
Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res (1995) 0.92
Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg (2000) 0.91
Population-based mapping of pulmonary adenoma susceptibility 1 locus. Cancer Res (2000) 0.91
Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res (1997) 0.90
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest (1992) 0.90
Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene (2007) 0.90
Surgical resection for pulmonary metastases of sweat gland carcinoma. Thorax (1994) 0.89
MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg (1999) 0.89
Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg (1997) 0.89
High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene (1997) 0.88
Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg (1994) 0.88
Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg (1997) 0.87
Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. Surg Oncol (1996) 0.87
p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer (1998) 0.87
Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer (1998) 0.86
Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res (1997) 0.86
Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. Carcinogenesis (1999) 0.86
Application of self-efficacy theory in dental clinical practice. Oral Dis (2010) 0.85
Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. J Clin Invest (1992) 0.85
Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. Br J Cancer (1991) 0.84
Prognostic value and clinicopathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res (1996) 0.83
N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res (1997) 0.83
Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. Biochem Biophys Res Commun (1991) 0.83
Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res (1996) 0.83
Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. Ann Thorac Surg (1993) 0.83
Combined resections of the diaphragm and the liver for a locally advanced non-small-cell lung cancer. Respiration (1996) 0.83
Polymorphism at codon 36 of the p53 gene. Oncogene (1994) 0.82
Detection of human papillomavirus DNA sequences in oral squamous cell carcinomas and their relation to p53 and proliferating cell nuclear antigen expression. Cancer (1995) 0.82
Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma. J Cancer Res Clin Oncol (1995) 0.82
Pulmonary dirofilariasis causing a solitary lung mass and pleural effusion. Thorax (1991) 0.82
Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene (2012) 0.81
Maximum length of tracheal autografts in dogs. J Thorac Cardiovasc Surg (1993) 0.81
p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol (1997) 0.80
A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer. Am J Respir Cell Mol Biol (1990) 0.80
Angiosarcoma of the chest wall with a gastric metastasis. Thorac Cardiovasc Surg (1993) 0.80
fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. Jpn J Cancer Res (1986) 0.80
[Delayed traumatic hernia diagnosed with magnetic resonance imaging]. Nihon Kyobu Shikkan Gakkai Zasshi (1997) 0.80
p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med (1998) 0.79
P450 in wild animals as a biomarker of environmental impact. Biomarkers (2001) 0.79
Effects of sodium n-butyrate on entry into S phase in resting rat 3Y1 cells infected with simian virus 40. J Virol (1985) 0.79
Topographical distributions of allelic loss in individual non-small-cell lung cancers. Am J Pathol (2000) 0.79
Lung adenocarcinoma is more sensitive than gastric adenocarcinoma to anticancer drugs in vitro. Eur J Surg Oncol (1991) 0.79
Transformation by v-H-ras does not restore proliferation of a set of temperature-sensitive cell-cycle mutants of rat 3Y1 fibroblasts. Cell Struct Funct (1990) 0.78
Video-assisted thoracoscopic surgery of bullous and bleb disorders of the lung using endoscopic stapling device. Surg Laparosc Endosc (1995) 0.78
Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg (2001) 0.78
Hepatic inflow vessels caliber as an index for liver function. Hepatogastroenterology (1996) 0.78
Selective cytotoxicity of phospholipids and diacylglycerols to rat 3Y1 fibroblasts transformed by adenovirus type 12 or its E1A gene. Cancer Res (1988) 0.78
Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biol Trace Elem Res (1994) 0.78
Time to first cigarette and lung cancer risk in Japan. Ann Oncol (2013) 0.78
CT and MRI manifestations of primary pulmonary plasmacytoma. Clin Imaging (1995) 0.78
Thoracoscopy in the management of intrathoracic neurogenic tumors. Int Surg (1997) 0.77
RT-PCR-based cytochrome P450 expression profile of oral tissue samples. J Clin Pharm Ther (2007) 0.77
Identification of an epitope from the epithelial cell adhesion molecule eliciting HLA-A*2402-restricted cytotoxic T-lymphocyte responses. Tissue Antigens (2004) 0.77
Abortive transformation of temperature-sensitive mutants of rat 3Y1 cells by simian virus 40: effect of cellular arrest states on entry into S phase and cellular proliferation. J Cell Physiol (1985) 0.77
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer (1994) 0.77